Risat Jannat, PhD MSD

Risat is currently a Director within Global Vaccines & Biologics Commercialization at Merck.  She has over 15 years of experience across both biologics and vaccines development and commercialization.  Risat led the cross-functional team responsible for facility start-up, technology transfer, and completion of accelerated regulatory approvals for ERVEBO®, the first vaccine against Ebola approved in the US, EU, and African countries.  Risat holds a BS in Biology from MIT and a PhD in Bioengineering from the University of Pennsylvania.